GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:GNVC
- CUSIP: N/A
- Web: www.genvec.com/
- 50 Day Moving Avg: $6.74
- 200 Day Moving Avg: $5.80
- 52 Week Range: $0.27 - $10.44
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.57
- P/E Growth: 0.000
- Net Margins: -3,748.25%
- Return on Equity: -648.22%
- Return on Assets: -271.77%
- Current Ratio: 2.10%
- Quick Ratio: 2.10%
- Average Volume: 28,534 shs.
- Beta: 3.34
Frequently Asked Questions for GenVec (NASDAQ:GNVC)
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
Shares of GenVec reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
How were GenVec's earnings last quarter?
GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings data on Friday, November, 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.07 million. GenVec had a negative return on equity of 648.22% and a negative net margin of 3,748.25%. View GenVec's Earnings History.
Where is GenVec's stock going? Where will GenVec's stock price be in 2017?
2 equities research analysts have issued 1 year price targets for GenVec's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate GenVec's share price to reach $7.00 in the next twelve months. View Analyst Ratings for GenVec.
Who are some of GenVec's key competitors?
Some companies that are related to GenVec include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN) and Nektar Therapeutics (NKTR).
Who are GenVec's key executives?
GenVec's management team includes the folowing people:
- Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
- Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
- William N. Kelley M.D., Independent Director
- Stefan D. Loren Ph.D., Independent Director
- Quinterol J. Mallette M.D., Independent Director
- Michael S. Richman, Independent Director
- Marc R. Schneebaum, Independent Director
How do I buy GenVec stock?
Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenVec's stock price today?
MarketBeat Community Rating for GenVec (NASDAQ GNVC)MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GenVec stock can currently be purchased for approximately $7.19.
Consensus Ratings for GenVec (NASDAQ:GNVC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$7.00 (2.68% downside)|
Analysts' Ratings History for GenVec (NASDAQ:GNVC)
(Data available from 9/25/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/25/2017||Rodman & Renshaw||Downgrade||Buy -> Neutral||$15.00 -> $7.00||N/A|
|7/26/2016||Roth Capital||Reiterated Rating||Buy||$80.00 -> $20.00||N/A|
Earnings History for GenVec (NASDAQ:GNVC)Earnings History by Quarter for GenVec (NASDAQ GNVC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/4/2016||Q3 2016||($0.08)||($0.05)||$0.07 million||$0.17 million||View||N/A|
|8/5/2016||Q116||($0.10)||($0.06)||$0.12 million||$0.03 million||View||N/A|
|5/12/2016||Q1 2016||($0.09)||($0.11)||$0.18 million||$0.29 million||View||N/A|
|3/9/2016||Q415||($0.08)||($0.10)||$0.21 million||$0.16 million||View||N/A|
|11/9/2015||Q3 2015||($0.11)||($0.09)||$0.15 million||$0.19 million||View||N/A|
|8/7/2015||Q215||($0.10)||($0.11)||$0.38 million||$0.13 million||View||N/A|
|5/8/2015||Q115||($0.06)||($0.09)||$0.91 million||$0.41 million||View||N/A|
|3/24/2015||Q414||$0.08||$0.11||$3.33 million||$3.50 million||View||Listen|
|11/12/2014||Q314||($0.09)||($0.10)||$1.00 million||$0.25 million||View||N/A|
|5/12/2014||Q114||$0.04||($0.07)||$2.00 million||$2.10 million||View||N/A|
|3/28/2014||Q413||($0.16)||($0.07)||$1.52 million||$0.15 million||View||Listen|
|11/12/2013||Q313||($0.23)||$2.10 million||$1.60 million||View||N/A|
|11/9/2012||Q312||($0.32)||($0.30)||$2.90 million||$2.13 million||View||N/A|
Earnings Estimates for GenVec (NASDAQ:GNVC)
Current Year EPS Consensus Estimate: $-2.500 EPS
Next Year EPS Consensus Estimate: $-2.800 EPS
Dividend History for GenVec (NASDAQ:GNVC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GenVec (NASDAQ:GNVC)
Insider Ownership Percentage: 8.10%Insider Trades by Quarter for GenVec (NASDAQ:GNVC)
Institutional Ownership Percentage: 6.22%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/16/2016||Douglas J Swirsky||CEO||Buy||10,000||$0.50||$5,000.00|| |
|12/14/2015||Douglas J Swirsky||CEO||Buy||5,000||$2.00||$10,000.00|| |
|11/16/2015||Stefan Loren||Director||Buy||4,000||$1.93||$7,720.00|| |
|8/11/2015||Douglas E Brough||Insider||Buy||4,600||$2.34||$10,764.00|| |
|5/27/2014||Ecor1 Capital, Llc||Major Shareholder||Buy||24,140||$2.24||$54,073.60|| |
|3/28/2014||Ecor1 Capital, Llc||Major Shareholder||Buy||122,273||$2.55||$311,796.15|| |
Headline Trends for GenVec (NASDAQ:GNVC)
Latest Headlines for GenVec (NASDAQ:GNVC)
|Head to Head Survey: Organovo Holdings (ONVO) and GenVec (GNVC)|
www.americanbankingnews.com - August 30 at 9:12 AM
|Intrexon Integrates Leading Adenoviral Gene Delivery Technology with ...|
www.prnewswire.com - June 17 at 10:55 PM
|Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition|
finance.yahoo.com - June 16 at 6:15 PM
|GenVec Inc (GNVC) Short Interest Update|
www.americanbankingnews.com - June 4 at 9:46 AM
|GenVec, Inc. :GNVC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017|
finance.yahoo.com - May 12 at 6:10 PM
| GenVec Inc (GNVC) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - May 12 at 10:56 AM
|How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma|
www.bizjournals.com - April 28 at 10:35 AM
|GenVec (GNVC) Given Daily News Impact Rating of 0.35|
www.americanbankingnews.com - April 28 at 12:06 AM
|GenVec (GNVC) Receiving Somewhat Favorable Media Coverage, Report Shows|
www.americanbankingnews.com - April 24 at 1:28 PM
|SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against GenVec, Inc.|
feeds.benzinga.com - April 17 at 9:21 PM
|GENVEC INC Financials|
finance.yahoo.com - March 10 at 6:39 PM
|GENVEC INC Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 6 at 5:07 PM
|WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders - PR Newswire (press release)|
www.prnewswire.com - February 8 at 11:04 PM
|WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders|
finance.yahoo.com - February 8 at 11:04 PM
|INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And Encourages Investors To Contact The Firm For Additional Information|
finance.yahoo.com - February 6 at 5:33 PM
|GENVEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenVec, Inc.|
finance.yahoo.com - February 2 at 6:04 PM
|Rodman & Renshaw Downgrades GenVec, Inc. (GNVC) to Neutral - StreetInsider.com|
www.streetinsider.com - January 26 at 6:57 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of GenVec, Inc. to Intrexon Corporation is Fair to Shareholders - GNVC|
finance.yahoo.com - January 26 at 6:56 PM
|Intrexon To Buy GenVec For $7 a Share (XON, GNVC)|
www.investopedia.com - January 25 at 4:51 PM
|GenVec downgraded by Rodman & Renshaw|
finance.yahoo.com - January 25 at 4:51 PM
|Intrexon To Buy GenVec In Stock Deal For $7/Shr|
www.investopedia.com - January 25 at 4:51 PM
|GenVec Inc. (GNVC) Is Up Sharply After Bought By Intrexon|
www.rttnews.com - January 24 at 6:14 PM
|GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit|
biz.yahoo.com - January 24 at 6:14 PM
|EnteroMedics and GenVec Post Substantial Gains as the NASDAQ is Pushed to Record High|
finance.yahoo.com - January 10 at 6:27 PM
|East Coast biotech company licenses Washington U technology|
www.bizjournals.com - January 9 at 4:18 PM
|GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington University in St. Louis|
us.rd.yahoo.com - January 5 at 6:28 PM
|8:12 am GenVec enters into an exclusive option agreement with Washington University in St. Louis to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting|
us.rd.yahoo.com - January 5 at 6:28 PM
GenVec (GNVC) Chart for Monday, September, 25, 2017